Close Menu

Which sequencing platform will win the race to the 30X, $1,000 genome? That's what Keith Robison at Omics! Omics! wants to know. Of all the existing platforms, two are close to what Robison calls the "arbimagical" goal — a goal which is arbitrary but has achieved a magical aura from being repeated so much. ABI's SOLiD 4 platform has been said to generate a $6,000 genome, and the SOLiD 4 hq upgrade is planned for this fall with a target of delivering a $3,000 genome, Robison says.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Russia says its candidate SARS-CoV-2 vaccine has a very high efficacy rate in an initial analysis of clinical trial data, according to the Financial Times.

Wired reports on a microbial analysis of sketches drawn by Leonardo DaVinci.

A new survey explores coronavirus vaccine hesitancy among Black and Latino individuals, the Washington Post reports.

In Nucleic Acids Research this week: the Aging Atlas database, a database of human metagenome-related metadata, and more.